Zobrazeno 1 - 10
of 77
pro vyhledávání: '"XINGXIANG XU"'
Autor:
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Jie Weng, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Hongying Wei, Jiawei Wei, Zheyu Zhang, Qiong Wu
Publikováno v:
Cancer Communications, Vol 44, Iss 9, Pp 1005-1017 (2024)
Abstract Background The initial randomized, double‐blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first‐line therapy in epidermal growth factor re
Externí odkaz:
https://doaj.org/article/2b6ae05d34ee40d883ed46122a1d5428
Publikováno v:
Mathematical Biosciences and Engineering, Vol 20, Iss 10, Pp 18063-18082 (2023)
To date, few studies have investigated whether the RNA-editing enzymes adenosine deaminases acting on RNA (ADARs) influence RNA functioning in lung adenocarcinoma (LUAD). To investigate the role of ADAR in lung cancer, we leveraged the advantages of
Externí odkaz:
https://doaj.org/article/abfddb72a473426d9a37045e0b09bb40
Autor:
Shun Lu, Hongming Pan, Lin Wu, Yu Yao, Jianxing He, Yan Wang, Xiuwen Wang, Yong Fang, Zhen Zhou, Xicheng Wang, Xiuyu Cai, Yan Yu, Zhiyong Ma, Xuhong Min, Zhixiong Yang, Lejie Cao, Huaping Yang, Yongqian Shu, Wu Zhuang, Shundong Cang, Jian Fang, Kai Li, Zhuang Yu, Jiuwei Cui, Yang Zhang, Man Li, Xinxuan Wen, Jie Zhang, Weidong Li, Jianhua Shi, Xingxiang Xu, Diansheng Zhong, Tao Wang, Jiajia Zhu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-11 (2023)
Abstract This phase I/II trial characterized the tolerability, safety, and antitumor activities of unecritinib, a novel derivative of crizotinib and a multi-tyrosine kinase inhibitor targeting ROS1, ALK, and c-MET, in advanced tumors and ROS1 inhibit
Externí odkaz:
https://doaj.org/article/abb77573f5db4043b5967b91a2aae0b2
Autor:
Tao Jiang, Jianhua Chen, Xingxiang Xu, Ying Cheng, Gongyan Chen, Yueyin Pan, Yong Fang, Qiming Wang, Yunchao Huang, Wenxiu Yao, Rui Wang, Xingya Li, Wei Zhang, Yanjun Zhang, Sheng Hu, Renhua Guo, Jianhua Shi, Zhiwu Wang, Peiguo Cao, Donglin Wang, Jian Fang, Hui Luo, Yi Geng, Chunyan Xing, Dongqing Lv, Yiping Zhang, Junyan Yu, Shundong Cang, Yaxi Zhang, Jiao Zhang, Zeyu Yang, Wei Shi, Jianjun Zou, Caicun Zhou, Shengxiang Ren
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase I
Externí odkaz:
https://doaj.org/article/e3a7e17ca1784e8baad00d8ae21907c5
Autor:
Jiaxin Chen, Tao Han, Mao Huang, Yi Yang, Futai Shang, Yishan Zheng, Wenjing Zhao, Liang Luo, Xudong Han, Aihua Lin, Hongsheng Zhao, Qin Gu, Yi Shi, Jun Li, Xingxiang Xu, Kexi Liu, Yijun Deng, Enzhi Jia, Quan Cao
Publikováno v:
Virulence, Vol 11, Iss 1, Pp 1557-1568 (2020)
Asymptomatic SARS-CoV-2-infected individuals are thought to play major roles in virus transmission. This study aimed to analyze the characteristics of asymptomatic carriers with COVID-19 to control the spread of the virus. We retrospectively investig
Externí odkaz:
https://doaj.org/article/153f402d001b418eb3229f9cb556fb71
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Malignant tumors are risk factors for a pulmonary embolism (PE), and a PE caused by a tumor is not uncommon. Primary pleural squamous cell carcinoma (PPSCC) is a rare malignancy; thus, a related PE is extremely rare. Case presenta
Externí odkaz:
https://doaj.org/article/b25d03ff73294604a37a54d4d59285d3
Autor:
Siqi Hu, Xiuxiu Wu, Wenshuai Xu, Xinlun Tian, Yanli Yang, Shao-Ting Wang, Song Liu, Xingxiang Xu, Kai-Feng Xu
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 14, Iss 1, Pp 1-7 (2019)
Abstract Background Sirolimus has been confirmed to be effective for lymphangioleiomyomatosis (LAM), a rare multisystem neoplastic disease in women. The long-term effects of sirolimus treatment for LAM, however, are largely unknown. We aimed to analy
Externí odkaz:
https://doaj.org/article/e768a481579143d9831ebf55d0bf9a51
Autor:
Yong Chen, Lingfeng Min, Chuanli Ren, Xingxiang Xu, Jianqi Yang, Xinchen Sun, Tao Wang, Fang Wang, Changjiang Sun, Xizhi Zhang
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0171751 (2017)
Lung cancer is the leading cause of cancer death in the world, and aberrant expression of miRNA is a common feature during the cancer initiation and development. Our previous study showed that levels of miRNA-148a assessed by quantitative real-time p
Externí odkaz:
https://doaj.org/article/6adb33efa2024ea49e57a6ec1cb07101
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0185316 (2017)
The association between height and lung cancer risk has been investigated by epidemiological studies but the results are inconsistent. This meta-analysis was to evaluate whether the height is associated with lung cancer.We identified relevant article
Externí odkaz:
https://doaj.org/article/9c3292cb66014f34b7abaf6c0706b08f
Autor:
Yutu, Luo, Suwei, Hu, Fang, Wang, Junjun, Yang, Daohui, Gong, Wenjing, Xu, Xingxiang, Xu, Lingfeng, Min
Publikováno v:
Translational Cancer Research. 11:3803-3813
Lung cancer is a common malignant tumor, with, non-small cell lung cancer (NSCLC) accounting for about 80-85% of cases. This study investigated the expression of miR-137 in NSCLC tissues and cells and its effects on the migration and invasion of NSCL